161 related articles for article (PubMed ID: 12792701)
1. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.
Santos VN; Lanzoni VP; Szejnfeld J; Shigueoka D; Parise ER
Braz J Med Biol Res; 2003 Jun; 36(6):723-9. PubMed ID: 12792701
[TBL] [Abstract][Full Text] [Related]
2. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
[TBL] [Abstract][Full Text] [Related]
3. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
5. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
[TBL] [Abstract][Full Text] [Related]
6. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial.
Méndez-Sánchez N; González V; Chávez-Tapia N; Ramos MH; Uribe M
Ann Hepatol; 2004; 3(3):108-12. PubMed ID: 15505596
[TBL] [Abstract][Full Text] [Related]
7. Jeune syndrome and liver disease: report of three cases treated with ursodeoxycholic acid.
Labrune P; Fabre M; Trioche P; Estournet-Mathiaud B; Grangeponte MC; Rambaud C; Maurage C; Bernard O
Am J Med Genet; 1999 Dec; 87(4):324-8. PubMed ID: 10588838
[TBL] [Abstract][Full Text] [Related]
8. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial.
Bellentani S; Tabarroni G; Barchi T; Ferretti I; Fratti N; Villa E; Manenti F
J Hepatol; 1989 Jan; 8(1):7-12. PubMed ID: 2564011
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
[TBL] [Abstract][Full Text] [Related]
10. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F
Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease.
de Jonge C; Rensen SS; Koek GH; Joosten MF; Buurman WA; Bouvy ND; Greve JW
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1517-20. PubMed ID: 23920034
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid for nonalcoholic steatohepatitis.
Wu SD; Li L; Wang JY
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1247-53. PubMed ID: 22864259
[TBL] [Abstract][Full Text] [Related]
14. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T
Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
[TBL] [Abstract][Full Text] [Related]
15. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
[TBL] [Abstract][Full Text] [Related]
16. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis.
Suzuki A; Lymp J; St Sauver J; Angulo P; Lindor K
Liver Int; 2006 Dec; 26(10):1209-16. PubMed ID: 17105586
[TBL] [Abstract][Full Text] [Related]
17. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
18. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
[TBL] [Abstract][Full Text] [Related]
19. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet.
Shidfar F; Bahrololumi SS; Doaei S; Mohammadzadeh A; Gholamalizadeh M; Mohammadimanesh A
Can J Gastroenterol Hepatol; 2018; 2018():1053710. PubMed ID: 29850450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
